Question 1

What is Apellis Pharmaceuticals?

Accepted Answer

Apellis Pharmaceuticals is a Company.

Question 2

How often does Apellis Pharmaceuticals appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 47 articles.

Question 3

When was Apellis Pharmaceuticals first tracked by Ergen?

Accepted Answer

First tracked on Apr 01, 2026.

Question 4

When was Apellis Pharmaceuticals last mentioned in news?

Accepted Answer

Last active on Jun 18, 2026.

Question 5

What is Apellis Pharmaceuticals's current news sentiment?

Accepted Answer

Aggregate sentiment score: -10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Apellis Pharmaceuticals in global news coverage?

Accepted Answer

Attention score of 2, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Apellis Pharmaceuticals?

Accepted Answer

Monteverde Investigates Multiple Mergers, Sales (Apr 01, 2026, 47 articles).

Question 8

How did the "Monteverde Investigates Multiple Mergers, Sales" event impact Apellis Pharmaceuticals?

Accepted Answer

Apellis Pharmaceuticals, Inc. is being sold to Biogen, Inc., with shareholders expected to receive $41.00 per share in cash and a contingent value right. Monteverde & Associates PC is investigating this sale.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.